Imagine a world where a simple urinary tract infection (UTI) could become a death sentence. This chilling scenario is closer than you think, as antibiotic-resistant E. coli strains are on the rise, claiming nearly 250,000 lives annually. But here's the glimmer of hope: researchers at the University of Alberta have pinpointed a new drug target that could revolutionize the fight against these deadly bacteria.
In a groundbreaking study published in Nature Communications (https://www.nature.com/articles/s41467-025-67697-2), the team uncovered the critical role of a protease called GlpG in E. coli’s ability to infect human cells and resist treatment. Located in the bacterial membrane, GlpG is essential for producing pili—tiny, hair-like structures that help E. coli latch onto tissues—and for forming biofilms, the protective shields that make bacteria nearly invincible against antibiotics and the immune system.
“GlpG is like the mastermind behind E. coli’s most dangerous tricks,” explains Dr. Joanne Lemieux (https://www.ualberta.ca/en/biochemistry/people/faculty/joanne-lemieux.html), a biochemistry professor and vice-dean of research at the Faculty of Medicine & Dentistry (https://www.ualberta.ca/en/medicine/index.html). “By inhibiting this protease, we can disarm the bacteria, preventing them from adhering to cells, invading tissues, and forming biofilms.”
The team’s experiments were striking: when GlpG was blocked in pathogenic E. coli, the bacteria lost their ability to infect bladder and kidney cells. Even more impressively, existing biofilms were eradicated, offering a potential solution for chronic infections. And this is the part most people miss: the researchers are now working on drugs that target GlpG specifically in harmful E. coli, leaving beneficial gut bacteria unharmed—a game-changer for minimizing side effects.
The urgency of this research cannot be overstated. Between 1990 and 2019, global UTI-related deaths surged by 140% (https://pmc.ncbi.nlm.nih.gov/articles/PMC9363895/), largely due to antibiotic resistance. Dr. Lemieux warns, “Antimicrobial resistance is a global emergency. By 2050, it’s projected to kill as many people as cancer.” The World Health Organization has even labeled E. coli a critical priority pathogen (https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance), underscoring the dire need for new treatments.
But here’s where it gets controversial: while UTIs are often associated with women, they devastate a far broader population. Pediatric patients, catheter users, and even survivors of kidney cancer or disease are at risk, often succumbing to urosepsis—a life-threatening complication. Pathogenic E. coli also play a role in inflammatory bowel disease, Crohn’s disease, and ureter stent blockages, which currently require invasive surgical interventions.
The discovery of GlpG as a drug target is particularly promising because up to 20% of E. coli infections are already resistant to existing antibiotics. Protease inhibitors, already used to treat conditions like HIV and COVID-19, provide a proven framework for developing new therapies. Dr. Lemieux’s lab, bolstered by experience gained during the pandemic and armed with several antiviral drug patents, is leading the charge.
However, drug development is a marathon, not a sprint. “It can take up to a decade to bring a new drug to market,” Dr. Lemieux admits. “But we can’t afford to wait. UTIs are so common that people assume antibiotics will always be there. We need to act now to ensure they remain effective.”
This research, a collaboration across biochemistry, medical microbiology, and pediatrics, was spearheaded by Jimmy Lu (https://apps.ualberta.ca/directory/person/jimmy5), whose PhD work laid the foundation. Now a Mitacs (https://www.mitacs.ca/) post-doctoral fellow with Applied Pharmaceutical Innovation (https://appliedpharma.ca/services/), Lu continues to push the boundaries in Dr. Lemieux’s lab.
Funded by organizations like the Canada Foundation for Innovation (https://www.innovation.ca/), the Natural Sciences and Engineering Research Council of Canada (https://nserc-crsng.canada.ca/en), and the Stollery Children’s Hospital Foundation, this work is a testament to the power of interdisciplinary collaboration.
Here’s the thought-provoking question: As antibiotic resistance accelerates, should we prioritize funding for drug development or focus on preventive measures like reducing antibiotic overuse? Share your thoughts in the comments—this is a conversation we all need to have.
Dr. M. Joanne Lemieux, also executive director of the PRAIRIE Hub for Pandemic Preparedness (https://www.ualberta.ca/en/prairie-hub-pandemic-preparedness/index.html), emphasizes that understanding E. coli’s virulence factors is just the first step. “We’re not just fighting bacteria; we’re fighting time,” she says. “The clock is ticking, and the world is watching.”
